Literature DB >> 3303969

Glucagon and insulin metabolism in a portal-hypertensive rat model.

E Sikuler, J Polio, R J Groszmann, R Hendler.   

Abstract

The role that portosystemic shunting plays in inducing the alterations of glucagon and insulin metabolism, which are observed in chronic liver disease, was studied in a rat model of prehepatic portal hypertension induced by portal vein constriction. Net splanchnic output of the hormones into the portal circulation was calculated from the difference between portal and systemic concentrations multiplied by portal plasma flow. Metabolic clearance rate was calculated as the ratio between output and systemic concentration. Portal blood flow was measured by the radioactive microsphere technique. Glucagon output in the portal vein-ligated rats was higher than in the sham-operated controls (5.9 +/- 1.5 vs. 2.0 +/- 0.2 ng/min, P less than 0.05). The metabolic clearance rate of glucagon was not significantly different between the two groups. Insulin output was not significantly different between the two groups; however, the metabolic clearance rate of insulin in the portal vein-ligated rats was reduced in comparison with the sham-operated group (9.5 +/- 1.5 vs. 18.4 +/- 3.3 ml/min, P less than 0.05). Our results indicate that portosystemic shunting per se is sufficient to cause an increased splanchnic output of glucagon into the portal system and a decreased metabolic clearance of insulin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3303969     DOI: 10.1152/ajpgi.1987.253.2.G110

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Activation of K(ATP) channels suppresses glucose production in humans.

Authors:  Preeti Kishore; Laura Boucai; Kehao Zhang; Weijie Li; Sudha Koppaka; Sylvia Kehlenbrink; Anna Schiwek; Yonah B Esterson; Deeksha Mehta; Samar Bursheh; Ya Su; Roger Gutierrez-Juarez; Radhika Muzumdar; Gary J Schwartz; Meredith Hawkins
Journal:  J Clin Invest       Date:  2011-11-07       Impact factor: 14.808

2.  Effect of a somatostatin analogue (SMS 201-995) on hemodynamics and glucagon secretion in cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; T Mori; K Kashima
Journal:  Gastroenterol Jpn       Date:  1993-04

3.  Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress.

Authors:  T J Johnson; E M Quigley; T E Adrian; G Jin; L F Rikkers
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

4.  Elevated NEFA levels impair glucose effectiveness by increasing net hepatic glycogenolysis.

Authors:  S Kehlenbrink; S Koppaka; M Martin; R Relwani; M-H Cui; J-H Hwang; Y Li; R Basu; M Hawkins; P Kishore
Journal:  Diabetologia       Date:  2012-07-31       Impact factor: 10.122

5.  Hyperinsulinemia and insulin resistance in a patient with type 2 diabetes complicated with myelofibrosis.

Authors:  Hidetaka Hamasaki; Shuichi Mishima; Hidekatsu Yanai
Journal:  World J Diabetes       Date:  2012-08-15

6.  Central KATP Channels Modulate Glucose Effectiveness in Humans and Rodents.

Authors:  Michelle Carey; Eric Lontchi-Yimagou; William Mitchell; Sarah Reda; Kehao Zhang; Sylvia Kehlenbrink; Sudha Koppaka; Sylvan Roger Maginley; Sandra Aleksic; Shobhit Bhansali; Derek M Huffman; Meredith Hawkins
Journal:  Diabetes       Date:  2020-03-26       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.